Breakthrough Discovery: New Cystic Fibrosis-Related Diabetes Biomarkers Offer Hope for Patients – European Medical Journal Insights

Cystic fibrosis-related diabetes (CFRD) is the most prevalent comorbidity associated with cystic fibrosis (CF), yet early detection remains challenging due to subtle glucose abnormalities. A recent study conducted in Denmark on a cohort of 93 adults with CF has shed light on the role of circulating microRNAs in distinguishing between different glucose tolerance statuses. Researchers aimed to determine if these microRNAs exhibit notable changes during an oral glucose tolerance test (OGTT), a commonly used diagnostic tool.

Participants in the study were categorized into four groups: normal glucose tolerance, indeterminate glucose tolerance, impaired glucose tolerance, and CFRD. Serum samples were collected before and at multiple intervals following glucose ingestion, allowing researchers to monitor real-time changes instead of relying on a single measurement. This dynamic assessment is crucial for understanding how glucose tolerance status impacts microRNA profiles.

Through detailed sequencing and subsequent validation, the study discovered microRNAs that not only differed at baseline but also responded distinctly to glucose intake. Notably, four microRNAs exhibited altered expression levels at the start, while other microRNAs displayed varying response patterns during the OGTT, depending on the participant’s glucose tolerance category. Among the findings, miR-34a-5p and miR-122-5p were elevated in individuals with indeterminate glucose tolerance and CFRD, correlating with increased markers of liver damage. The third microRNA candidate, miR-223-3p, demonstrated unique response patterns during the OGTT, reinforcing the idea that these circulating molecules may serve as critical indicators of metabolic state in individuals with CF.

To probe the potential implications of these findings, researchers evaluated the effects of the identified microRNAs on insulin-secreting cells. They discovered that overexpressing miR-122-5p and miR-223-3p enhanced glucose-stimulated insulin secretion, while increasing miR-34a-5p levels led to decreased cell viability. These insights suggest that circulating microRNAs could play a significant role in the diagnosis and management of cystic fibrosis-related diabetes, indicating a possible connection between metabolic organs and the endocrine pancreas.

The research underscores the potential of microRNAs as biomarkers that can support clinical evaluations of CFRD, providing a timely and effective approach to monitoring this condition. As researchers continue to explore the functional relevance of these findings, the hope is that microRNA profiling could become a standard diagnostic tool in managing CF, ultimately improving patient outcomes.

Reference: Westholm E et al. Dynamic changes in circulating microRNAs during oral glucose tolerance testing support their potential as diagnostic and monitoring biomarkers in cystic fibrosis-related diabetes. Diabetologia. 2026; doi:10.1007/s00125-025-06645-7.

Original Source: https://www.emjreviews.com/respiratory/news/new-cystic-fibrosis-related-diabetes-biomarkers-emerge/
Category :
Tags:
Publish Date: 2026-02-07 13:34:00